z-logo
open-access-imgOpen Access
527. New Robust Antimicrobial Stewardship Program (ASP) Results in Reduction of Clostridium difficile 30-Day Readmission
Author(s) -
Jennifer Anthone,
Anum Abbas,
Bryan Alexander,
Dayla Boldt,
Sumaya Ased,
Cassara Carroll,
Stephen J. Cavalieri,
John Horne,
Manasa Velagapudi,
Carrie Valenta,
Giri Andukuri,
Richard Albert Paguia,
Michael Petzar,
Thamer Kassim,
Elizabeth George,
E Magliulo,
Christopher J. Destache,
Renuga Vivekanandan
Publication year - 2018
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofy210.536
Subject(s) - medicine , antimicrobial stewardship , clostridium difficile , reimbursement , antibiotics , health care , medical record , emergency medicine , medical emergency , antibiotic resistance , microbiology and biotechnology , economics , biology , economic growth
Background As the pipeline for antibiotics is decreasing and antibiotic resistance is increasing, it is critically important to be stewards of antibiotics. ASP has become a mandated program as of January of 2017 by Joint Commission and condition of participation for CMS on reimbursement. A pilot program of C. difficile treatment in the academic medical center proved to be quite useful to adapt to a larger healthcare system. Methods A dedicated Infectious Disease physician and three Antibiotics stewardship pharmacists (ASP) were hired to run this program. Goals of the program was to decrease broad-spectrum antibiotics use, and reduce Clostridium difficile readmission (CDR) for the healthcare system. Performance of CDR for each inpatient was accomplished with ASP making recommendations for treatment. Queries were built into the ASP software and alerts were generated in the electronic medical record (EMR). CDR was targeted daily for ASP pharmacists/ID physician. Comparison of fiscal year 2017 (control group) with 2018 (intervention group) was performed. Results CDR was reduced (control group 17.53% vs. intervention group 14.12%), respectively, for our healthcare system (P > 0.05). However, overall cost savings for the healthcare system was $1.3 million was realized. In the academic medical center specifically, with over 400 beds there was a significant reduction in CDR (control group 21% to intervention group 10.5% (P < 0.05). Cost savings estimated from CDR were $610,923. Finally, length of stay was reduced by 1 day for inpatients with C. difficile admission in the academic medical center. Conclusion ASP not only has immediate impact on patient care and safety but also can play a large role in treating the appropriate disease state and reduces unnecessary readmission to the acute care hospitals in our healthcare system. Disclosures All authors: No reported disclosures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom